Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101381 | 0.87 | BRD4 (0.39) | BRD4 | |
| SCHEMBL6099356 | 0.86 | PTGS2 (0.39) | HTR6BRD4 | |
| SCHEMBL6101905 | 0.85 | KDR (0.36) | BRD4GRIN1GRIN2B | |
| SCHEMBL6099817 | 0.81 | ADORA3 (0.31) | — | |
| SCHEMBL6102485 | 0.72 | DPP4 (0.32) | HTR6KCNH2 | |
| SCHEMBL6102129 | 0.72 | TLR8 (0.34) | BRD4 | |
| SCHEMBL6101986 | 0.71 | BRD4 (0.33) | TGFBR1BRD4 | |
| SCHEMBL8353835 | 0.69 | TLR8 (0.38) | HTR6KCNH2 | |
| SCHEMBL4762545 | 0.67 | PDE2A (0.31) | — | |
| SCHEMBL3072991 | 0.67 | GRM2 (0.47) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | NEUROGEN CORPORATION | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | HTR6 736/4885KCNH2 566/4885TGFBR1 573/4885 |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | HTR6 573/4885KCNH2 1618/4885TGFBR1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.